Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (88,881)	$ (226,539)	$ (247,116)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,246	1,655	1,437
Inventory obsolescence	1,350	422	932
Stock-based compensation expense	65,413	55,615	44,701
Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs	67,607	85,803	98,918
Amortization of premium (discount) on investments, net	(11,473)	(10,263)	(1,777)
Loss on extinguishment of debt	0	29,019	0
Loss on impairment	0	1,548	0
Changes in operating assets and liabilities:
Receivables	(22,698)	(6,095)	(21,470)
Inventory	(4,164)	(1,450)	(12,423)
Prepaid expenses and other assets	1,959	(6,820)	(2,583)
Accounts payable and accrued expenses	(62,379)	(16,806)	(22,360)
Deferred revenue	0	(1,230)	(109)
Net cash used in operating activities	(52,020)	(95,141)	(161,850)
Cash flows from investing activities:
Acquisitions of property and equipment	(1,124)	(2,168)	(1,351)
Purchases of investments	(266,763)	(514,407)	(244,283)
Maturities of investments	320,480	385,077	117,396
Net cash provided by (used in) investing activities	52,593	(131,498)	(128,238)
Cash flows from financing activities:
Net proceeds from common stock issued under stock-based compensation plans	3,444	8,340	14,765
Common stock issued to directors in lieu of cash retainer	34	342	190
Withholding taxes paid on stock-based awards	(7,535)	(2,172)	0
Net proceeds from secured term loans	0	300,000	73,072
Repayment of Athyrium secured term loans principal	0	(240,452)	0
Prepayment and repayment fees on Athyrium secured term loans	0	(21,261)	0
Payment of debt issuance costs on Pharmakon Tranche A term loan	0	(11,147)	0
Principal payments on finance lease liabilities	(1,704)	(1,165)	0
Net cash (used in) provided by financing activities	(5,761)	32,485	88,027
Effect of exchange rates on cash, cash equivalents and restricted cash	(936)	362	566
Decrease in cash, cash equivalents and restricted cash	(6,124)	(193,792)	(201,495)
Cash, cash equivalents and restricted cash at beginning of year	112,447	306,239	507,734
Cash, cash equivalents and restricted cash at end of year	106,323	112,447	306,239
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	104,713	110,643	304,767
Restricted cash	210	1,804	1,472
Restricted cash in other assets	1,400	0	0
Total cash, cash equivalents and restricted cash	106,323	112,447	306,239
Supplemental cash flow disclosure:
Cash paid for interest	30,383	22,139	0
Cash paid for taxes	1,603	1,434	3,542
Taxes withheld on stock-based awards included in accrued expenses	$ 758	$ 4,199	$ 1,990